DIG
ERNA icon

Dauntless Investment Group’s Eterna Therapeutics ERNA Stock Holding History

Dauntless Investment Group’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Sell
6,000
-18,498
-76% -$131K 0.03% 52
2026
Q1 		$122K Buy
+24,498
New +$391K 0.08% 51

Other funds holding ERNA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Dauntless Investment Group's ERNA Position: Q2 2026 in Review

Dauntless Investment Group reduced its Eterna Therapeutics (ERNA) stake by 76% in Q2 2026, selling an estimated $131K and leaving 6,000 shares worth $39.9K. The position accounts for 0.03% of the portfolio, ranked #52.

Dauntless Investment Group first reported a position in ERNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $122K in Q1 2026. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Dauntless Investment Group held 6,000 shares of Eterna Therapeutics worth $39.9K as of Q2 2026.
  • Dauntless Investment Group sold 18,498 Eterna Therapeutics shares in Q2 2026, an estimated $131K.
  • Eterna Therapeutics made up 0.03% of Dauntless Investment Group's portfolio in Q2 2026, its #52 holding.
  • Dauntless Investment Group first reported a position in Eterna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Dauntless Investment Group's Eterna Therapeutics position peaked at $122K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.